RxDoctor Payments Data

Paul Resignato, DPM

Foot Surgery · El Paso, TXNPI 1093799249

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,838 of the $7,095 with a category attached, or 68.2%. It is spread thinly across 21 manufacturers, the largest accounting for just 18.6%. Reporting peaked in 2019 at $2,156 and has fallen 70.3% since, to $639 in 2025.

$7,095in general payments, 2019–2025

Across 121 payments — averaging $58.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paragon 28, Inc.$1K
  • Treace Medical Concepts, Inc.$1K
  • Organogenesis Inc.$843
  • Integra Lifesciences Corporation$755
  • Smith+Nephew$698
  • Kerecis Limited$676
  • plus $2K from 15 others

What the payments were for

  • Speaking & faculty fees$1252%
  • Travel & lodging$1,70624%
  • Food & beverage$4,83868%
  • Education$1001%
  • Other$3265%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,095 in reported general payments places this provider in the 75th percentile of 71 foot surgery providers in Texas.

See all foot surgery providers in Texas

Medicare billing

Part B allowed, 2024
$109,119
Medicare patients
44
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox40$1,552
Ammonium Lactate28$644

Paid to pharmacies, not to this prescriber.

Other foot surgery in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →